Full-Time
Marketing Product Manager
Research Instruments
Updated on 9/16/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
Compensation Overview
$154.1k - $246.6k/yr
Milpitas, CA, USA
Remote
Bachelor's
 Growth & Marketing (1) |
|---|
Get referred to Becton Dickinson
See people who can refer or advise you
- A bachelor's degree in science, engineering, marketing, or an equivalent field is required.
- At least 5 years of experience in product marketing, marketing management, or commercial roles within life sciences or technology-driven markets is required.
- Demonstrated success leading regional go-to-market strategies and complex capital product launches.
- Strong experience partnering with sales leadership and field applications teams is required.
- Proven ability to influence across a matrixed organization without direct authority is required.
- Excellent communication, analytical, and business acumen.
- Own the United States regional go-to-market strategy for the Research Instruments portfolio, including major platform launches, lifecycle management, and portfolio optimization.
- Translate global product strategy into region-specific positioning, segmentation, and value propositions tailored to capital purchasing decisions.
- Develop and maintain positioning and messaging architecture for campaigns, sales tools, and customer conversations.
- Partner with Field Applications to translate workflows into application claims, demo stories, and configuration guidance.
- Define regional launch standards and ensure consistent execution across instrument platforms and configurations.
- Drive pipeline creation, opportunity quality, and win-rate improvement through coordinated regional marketing and field execution.
- Own the regional segmentation and prioritization model to focus coverage and improve conversion in high-value segments.
- Partner with Sales Operations and Finance on forecasting inputs and provide regular readouts on risks, upside, and mitigation actions.
- Partner with Growth Marketing on top-of-funnel awareness and consideration while owning downstream conversion and deal support.
- Identify gaps in pipeline coverage, segment penetration, and deal progression, and recommend corrective actions.
- Lead regional pricing, discounting guidance, and promotional strategy in collaboration with pricing, finance, and sales leadership.
- Own and communicate regional pricing strategy, including list price, promotional levers, bundles, configurations, and services or accessories attachment.
- Establish deal governance and guardrails, and coach the field on value framing and negotiation best practices.
- Support complex deal strategy, configuration guidance, and value-based selling for priority and strategic accounts.
- Partner with Finance and Sales Operations on pricing analytics and recommend corrective actions.
- Evaluate commercial performance, competitive dynamics, and deal outcomes to inform adjustments and recommendations.
- Provide senior-level sales and field enablement leadership for capital equipment, including playbooks, launch kits, competitive tools, and messaging frameworks.
- Partner with Regional Sales Leadership and Field Applications to align marketing priorities with coverage models, territory needs, and sales motions.
- Act as a subject-matter expert for Research Instruments in regional sales meetings, trainings, customer briefings, and planning forums.
- Lead regional voice-of-customer and key opinion leader engagement to inform instrument positioning, roadmap input, and commercial strategy.
- Synthesize customer, field, and market insights into actionable recommendations for Global Product Management.
- Monitor competitive platforms, buying criteria, and adoption trends, providing insights to regional and global stakeholders.
- Serve as the regional marketing lead for Research Instruments within annual operating plans, quarterly business reviews, and strategic planning processes.
- Influence roadmap prioritization, launch sequencing, and regional investment decisions using market-backed insights.
- Mentor and guide junior product and marketing managers through informal leadership and best-practice sharing.
- Experience marketing research instruments, capital equipment, or complex platforms.
- Familiarity with deal-based selling, pricing strategy, and discount governance.
- Experience working closely with global product management teams.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 9%1 year growth
↑ 9%2 year growth
↑ 9%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.